Furthermore, there was an obvious increase in the frequency of ER-negative tumours in the HMGCS1-intermediate (42%) and -high (56%) tumours (Fig 4B), as well as an increase in p53 mutation in ERα-positive tumours (Fig 4C). This evidence concerns the gene TP53 and neoplasm.